Multimodal assessment of the GABA system in patients with fragile-X syndrome and neurofibromatosis of type 1-Reference-Cited by-同舟云学术

Multimodal assessment of the GABA system in patients with fragile-X syndrome and neurofibromatosis of type 1

Published:2022-11 Issue: Volume:174 Page:105881
ISSN:0969-9961
Container-title:Neurobiology of Disease
language:en
Short-container-title:Neurobiology of Disease

Author:

Lacroix Angelina,Proteau-Lemieux Mélodie,Côté Samantha,Near Jamie,Hui Steve C.N.,Edden Richard A.E.,Lippé Sarah,Çaku Artuela,Corbin François,Lepage Jean-François

Publisher

Elsevier BV

Subject

Neurology

Reference87 articles.

1. A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I;Bearden;Ann. Clin. Translat. Neurol.,2016

2. ERK/MAPK pathway regulates GABAA receptors;Bell-Horner;J. Neurobiol.,2006

3. Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome;Berry-Kravis;Nat. Rev. Drug Discov.,2017

4. The GABAA receptor as a therapeutic target for neurodevelopmental disorders;Braat;Neuron,2015

5. Aberrant basal ganglia metabolism in fragile X syndrome: a magnetic resonance spectroscopy study;Bruno;J. Neurodev. Disord.,2013

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neurophysiological effects of a combined treatment of lovastatin and minocycline in patients with fragile X syndrome: Ancillary results of the LOVAMIX randomized clinical trial;Autism Research;2024-09-09

2. mTOR in metabolic homeostasis and disease;Experimental Cell Research;2024-08

3. Implication of the endocannabidiome and metabolic pathways in fragile X syndrome pathophysiology;Psychiatry Research;2024-07

4. Impact of trametinib on the neuropsychological profile of NF1 patients;Journal of Neuro-Oncology;2024-03-05

5. Time-frequency analyses of repetition suppression and change detection in children with neurofibromatosis type 1;Brain Research;2023-11